Remove Development Remove FDA Approval Remove Generic Pharmaceutical Remove Life Science
article thumbnail

Excellence Awards 2022 – Winners Announced!

Pharmaceutical Technology

The company has partnered with life sciences-focused investors Sixth Street and Royalty Pharma with an aim to bring substantial non-dilutive, low-cost capital to boost innovation and growth. billion to expedite research and development (R&D) for infectious diseases in lower-income countries.

Insulin 130
article thumbnail

Novartis’ Sandoz Launches Biosimilars Awareness Campaign to Improve Biosimilars Adoption Worldwide

XTalks

Sandoz is a pioneering leader in generic pharmaceuticals and biosimilars, as Sandoz launched the world’s first biosimilar in Europe in 2006 and won the first biosimilar approval in the US in 2014. Related: Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar. billion in 2021 to a high of $44.7

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98